nelarabine (506U78)

07/01/2009 - "Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: A case report and review of the literature."
07/01/2006 - "This review presents a new compound, nelarabine, that has shown efficacy in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma."
10/01/2009 - "Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma."
01/01/2009 - "Therefore, this unique drug feature of nelarabine accounts for clinical utilization in treating adult and pediatric patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. "
01/01/2009 - "Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia."

03/01/2008 - "Phase I trial of nelarabine in indolent leukemias."
12/01/2013 - "Nelarabine is more cytotoxic in T-lineage than in B-lineage leukemias. "
07/01/2006 - "Nelarabine use in leukemias."
06/01/2005 - "Nelarabine has significant activity against malignant T-cells and appears to be an important addition to treatments of various leukemias."
06/01/2005 - "Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias."

05/20/2005 - "Further studies are planned to determine whether the addition of nelarabine to front-line therapy for T-cell leukemia in children will improve survival."
05/20/2005 - "Nelarabine is active as a single agent in recurrent T-cell leukemia, with a response rate more than 50% in first bone marrow relapse. "
01/01/1999 - "2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine (GW506U78), a prodrug of arabinosylguanine (ara-G), is effective in T-cell leukemias. "
12/01/2006 - "We used low dose clofarabine and induced a remission in a patient who relapsed in the skin and marrow after allogeneic transplant and was refractory to nelarabine and report a near complete response, suggesting significant activity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias."

05/20/2005 - "Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies."
01/01/2010 - "After being first synthesized in the late 1970s and receiving FDA approval in 2005, the appropriate use of nelarabine for refractory hematologic malignancies is still being elucidated. "
11/01/1998 - "GW506U78 is an effective prodrug and a potent agent for hematologic malignancies with major efficacy in T-cell diseases. "
11/01/1998 - "Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response."
01/01/2009 - "This article reviews the pharmacology, mechanism of action, and pharmacokinetic properties of nelarabine, as well as nelarabine's clinical efficacy in T-ALL, T-LBL, and other hematologic malignancies. "

06/01/2011 - "The safety, tolerability, pharmacokinetics and efficacy of nelarabine were evaluated in adult and pediatric patients with relapsed or refractory T-ALL/T-LBL. "
09/29/2011 - "This largest study so far with nelarabine in adults showed impressive single-drug activity in relapsed T-ALL/T-LBL. "
06/01/2011 - "[Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL]."
02/01/2007 - "The JPLSG/ALL committee was started in 2005 for discussing the ongoing need for cooperative clinical study in Japan and the possibility of nelarabine-containing regimen for T-ALL."
08/13/2015 - "The use of nelarabine for relapsed and refractory T-ALL results in responses in a substantial minority of patients. "